RESUMEN
Teveten (eprosartan mesilate) was used as a monotherapy or in combination with hypotiazide (12,5 mg/day) in dosage 600 mg once a day for treatment of 20 patients with cerebrovascular pathology (chronic cerebrovascular insufficiency, consequences of brain ischemica in the presence of arterial hypertension stage I-II, or higher borderline levels of normal blood pressure (BP). Treatment duration was 12 weeks, 24-h monitoring of BP was made some indices of cerebral blood flow, hemodynamics and peripheral vessels reaction were registered. Modulating antihypertensive effect of Teveten was found, statistically significant reduction of systolic BP did not result in worsening of cerebral hemodynamics. Moreover, there was an improvement of endothelial function. Therefore, teveten may be recommended for treatment of patients with cerebrovascular pathology both with arterial hypertension and higher borderline BP.
